ABUS - Arbutus Biopharma Corporation
2.1000 +0.01 (0.48%)
Pre-Market: 8:00AM EDT
Chart Events
Long-term KST
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 2.1600 |
| Open | 2.1300 |
| Bid | 2.1100 x 2200 |
| Ask | 0.0000 x 800 |
| Day's Range | 2.0000 - 2.2500 |
| 52 Week Range | 0.8200 - 3.6600 |
| Volume | 1,043,133 |
| Avg. Volume | 1,109,359 |
| Market Cap | 144.129M |
| Beta (5Y Monthly) | 2.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5920 |
| Earnings Date | Aug 03, 2020 - Aug 07, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.32 |
Fair Value
Related Research
- GlobeNewswire
Arbutus to Present at Jefferies Virtual Healthcare Conference
WARMINSTER, Pa., May 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.
- Zacks
Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
- Benzinga
P/E Ratio Insights for Arbutus Biopharma
In the current session, Arbutus Biopharma Inc. (NASDAQ: ABUS) is trading at $2.43, after a 29.79% increase. Over the past month, the stock increased by 103.10%, and in the past year, by 16.12%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 33.69%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do not expect the stock to perform better in the future, and that the company is probably undervalued. It shows that shareholders are less than willing to pay a high share price, because they do not expect the company to exhibit growth, in terms of future earnings.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 7.28 in the biotechnology industry, Arbutus Biopharma has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.P/E ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 15 Healthcare Stocks Moving In Monday's Pre-Market Session * Arbutus Biopharma: Q1 Earnings Insights(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
Arbutus Biopharma Corporation (ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound. At week 12, the 60 mg single-dose achieved equivalent reductions in HBsAg as the 180 mg single-dose.
- Simply Wall St.
Forecast: Analysts Think Arbutus Biopharma Corporation's (NASDAQ:ABUS) Business Prospects Have Improved Drastically
Celebrations may be in order for Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders, with the analysts...
- Zacks
Why Arbutus (ABUS) Stock Might be a Great Pick
Arbutus (ABUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- Zacks
Arbutus' Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Arbutus Biopharma.
- TipRanks
3 “Strong Buy” Penny Stocks With Triple-Digit Upside
Given the troubling state of the U.S. economy, what’s driving the bullish sentiment on Wall Street? Stimulus.Among the bulls is chief investment strategist at CFRA, Sam Stovall, who estimates that the S&P 500 will hit 3,435 within a year. From current levels, this would reflect a double-digit gain, and come in above the 3,393 high-point posted on February 19. Back in March, he even went so far as to call for a new high in the third quarter, but since then he has updated his forecasts.“We’ve had a lot of people compare it with the Crash of ’29, the Depression of the 1930s, etc. But back then, you had the government actually tightening their reins, balancing their budget — you did not have a reactive Federal Reserve,” Stovall stated. He added, “Who’s to say we don’t go for a retest first? That’s a normal situation. However, I don’t think we’re going to get an even lower low because of the stimulus already injected into the system.”To this end, risk-tolerant investors are looking to take advantage of lower share prices, which present more attractive entry points. What’s the advantage of stocks with bargain price tags, specifically those trading for less than $5 per share? Should these names, which are deemed “penny stocks," experience even minor share price appreciation, it can translate to massive percentage gains.Therefore, huge returns are on the table, but penny stocks aren’t everyone’s cup of tea. Some argue that there could be a good reason they are trading at such low levels, and that the risk outweighs the potential rewards. Understanding the risk involved, we wanted to see if we could track down any compelling penny stocks in the healthcare space. Using TipRanks’ database, we pinpointed three that have received enough support from Wall Street analysts to earn a “Strong Buy” consensus rating. The cherry on top? All three of the tickers could double in the next year. Let’s dive in.Marinus Pharmaceuticals, Inc. (MRNS)Focused on the development of neuropsychiatric therapeutics, Marinus is one of the top players in the orphan epileptic disorder space. Following a first quarter update on the company’s progress, Wall Street believes its long-term growth narrative is strong and that its $2.06 share price reflects the ideal entry point.As part of the update, management announced that the design and dosing for the RSE pivotal Phase 3 trial for its lead development candidate, ganaxolone (GNX), had been confirmed, with it set to begin in the third quarter. The co-primary endpoints for the trial are status cessation within 30 minutes and suppression for at least 24 hours, and it will be powered 90% to hopefully show 30% efficacy for GNX when compared to the placebo. Commenting for Oppenheimer, analyst Jay Olson said, “We view pivotal Phase 3 design as similar to positive Phase 2 trial while benefiting from longer dosing with 12 hours exposure vs. 8 hours prior. MRNS expects top-line data in the first half of 2022.”Additionally, the company finished enrolling participants for its CDD pivotal Phase 3 MARIGOLD trial, with the top-line data also slated for release in the third quarter. Olson argues that the discontinuation rate of less than 10% and high enrollment rate imply that tolerability levels are “favorable." The analyst added, “Pre-commercialization and NDA filing preparations remain on track despite COVID-19. We believe MRNS could have a substantial competitive advantage as a first mover.”If that wasn’t enough, Olson thinks the TSC Phase 2 open-label trial, which should start screening patients in Q2 and could see top-line data published in Q1 2021, could serve as a significant catalyst for shares. While COVID-19's impact on enrollment caused management to downsize the PRE Phase 3 VIOLET trial into a Phase 2 proof-of-concept trial in order to reprioritize resources, MRNS still has plenty going for it.“We view MRNS as well-positioned despite potential COVID-19 disruptions, with $77.8 million cash balance providing runway into 3Q21. We view MRNS's pipeline as attractive with multiple opportunities and several key near-term catalysts. We believe the current share price provides an attractive entry point,” Olson explained.To this end, Olson kept his Outperform call and $6 price target as is. Should this target be met, a twelve-month gain of 191% could be in store. (To watch Olson’s track record, click here) What does the rest of the Street think about Marinus’ long-term growth prospects? It turns out that other analysts also have high hopes. Only Buy ratings have been received in the last three months, so the consensus rating is a Strong Buy. In addition, the $5.50 average price target suggests 168% upside potential. (See Marinus stock analysis on TipRanks)Arbutus Biopharma Corporation (ABUS)With a diverse chronic hepatitis B virus (HBV) product pipeline including direct antiviral, host targeting and immune-based approaches, Arbutus Biopharma wants to develop a cure for the condition. Currently going for $1.65 apiece, several members of the Street think now is the time to get on board as multiple catalysts are fast-approaching.On May 11, the company revealed that it plans to share further results from the week 12 portion of the 60 mg single-dose cohort evaluating its lead candidate, a GalNAc delivered RNAi compound, AB-729, in the second quarter of 2020.Five-star analyst Mayank Mamtani, of B.Riley FBR, points out that preliminary data from the Phase 1a/1b AB-729 HBV study showed an HBsAg reduction comparable to advanced RNAi peers, even though it enrolled difficult to treat e-antigen negative patients. As HBsAg reduction rose during the study, the analyst argues that this increases the chances of successful follow-up data.On top of this, ABUS has several ongoing preclinical studies that are progressing right on track, enabling it to advance its next-generation oral capsid inhibitor, AB-836, into the clinic in 2021. This goes hand in hand with the company’s research efforts to develop an oral HBV RNA-destabilizer and an oral anti-PD-L1 inhibitor. Expounding on this, Mamtani commented, “Building on learnings from the previously discontinued AB-506, AB-836 offers increased potency and an enhanced resistance profile with ongoing IND-enabling studies inclusive of a new assay to help better characterize the safety profile.” It should also be noted that ABUS is going to start working on a therapy for coronaviruses, specifically targeting RNA-dependent polymerase, nsp12, and viral protease, which play key roles in the replication and transcription cycle of COVID-19. Mamtani thinks this approach is promising as Gilead’s experimental COVID-19 treatment, remdesivir, is a nucleotide analog that binds nsp12, which inhibits viral proliferation and produces clinical benefits.Mamtani added, “Nsp12 has also been implicated in HCV, HIV, and, notably, HBV, areas in which ABUS has extensive antiviral development expertise. In concert with the biotech and pharma COVID-19 consortium, ABUS anticipates pooling resources along with leveraging primary screening and lead optimization capabilities to advance novel candidates against known and unknown targets, which works ideally as a pan coronavirus agent in order to also prepare for future outbreaks.”Based on all of the above, it’s no wonder Mamtani reiterated his bullish call. Given the $6 price target, shares could soar 253% in the next twelve months. (To watch Mamtani’s track record, click here) Turning now to the rest of the Street, other analysts are on the same page. With 100% Street support, or 3 Buy ratings to be exact, the consensus is unanimous: ABUS is a Strong Buy. The $5 average price target brings the upside potential to 198.5%. (See Arbutus Biopharma stock analysis on TipRanks)Geron Corporation (GERN)Last but not least we have Geron, which is primarily focused on the development of imetelstat, a small molecule telomerase inhibitor active in the treatment of highly transfusion-dependent MDS and r/r myelofibrosis (MF). While it’s very likely that the company will experience some delays as a result of COVID-19, the Street cites its promising technology and bargain $1.36 share price as making it a compelling healthcare play.Some investors have expressed concern regarding GERN’s announcement that it won’t be able to complete enrollment for the Phase 3 IMerge trial by 2020 due to the impact of COVID-19. BTIG analyst Thomas Shrader acknowledges that the delay will push back imetelstat’s approval and launch, which he now thinks will come in 2024 instead of 2023. However, he argued, “Geron’s patients are as desperate as they come in r/r MDS and AML and we expect data to date leave physicians and patients highly motivated to find something to try.”Further explaining the MDS opportunity, Shrader believes the program demonstrates robust levels of durability. Not only does the five-star analyst call the 24-week RBC-TI rate “highly compelling”, but he also highlights the strong safety profile.Shrader said, “Greater than 90% of patients with neutropenias and thrombocytopenias had these AEs resolve prior to the next dose. This reversibility is in contrast to both HMAs and Revlimid where these toxicities result in drug interruptions. A KOL recently commented that the high 68% HI-E response suggests most patients receive some benefit – making any subsequent trials very easy to enroll.”It should be noted that previously, its IMbark trial had a 32% discontinuation rate thanks to lack of efficacy, but Shrader thinks “these discontinuations may have been premature due to the drug’s slow onset of action and its ‘black box nature’ during the trial.” He added, “Based on increased understanding of how imetelstat works and its promise as a therapeutic, this discontinuation rate is likely to be low in subsequent trials. Imetelstat seems likely to be used after luspatercept in RS+ MDS but could be the only drug after ESAs in other forms of the disease (including RS-).”With GERN working out the MF trial design and hoping to discuss the regulatory path forward with the FDA in Q2, the deal is sealed for Shrader. Along with a Buy rating, he did trim the price target from $4 to $3, but this still leaves room for 114% upside potential. (To watch Shrader’s track record, click here)All in all, other analysts echo Shrader’s sentiment. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $3.50 average price target, the upside potential comes in at 149%. (See Geron stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- GlobeNewswire
Arbutus to Present at UBS Virtual Global Healthcare Conference
WARMINSTER, Pa., May 12, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.
- Zacks
Moving Average Crossover Alert: Arbutus Biopharma
Arbutus Biopharma Corporation (ABUS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
- Zacks
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 21.88% and -17.62%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- Benzinga
Arbutus Biopharma: Q1 Earnings Insights
Shares of Arbutus Biopharma (NASDAQ:ABUS) rose 12.6% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share rose 46.81% year over year to ($0.25), which beat the estimate of ($0.39).Revenue of $1,491,000 rose by 113.00% year over year, which beat the estimate of $220,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 11, 2020View more earnings on ABUSTime: 07:05 PM ETWebcast URL: https://edge.media-server.com/mmc/p/r2c9xashPrice Action Company's 52-week high was at $3.66Company's 52-week low was at $0.82Price action over last quarter: down 53.20%Company Overview Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops and commercializes cure for patients suffering from Hepatitis B infection. It is focused on developing a portfolio of drug candidates with multiple mechanisms of action and also involved in licensing of Lipid nanoparticle technology.See more from Benzinga * Stocks That Hit 52-Week Lows On Friday * P/E Ratio Insights for Riot Blockchain * Stocks That Hit 52-Week Highs On Friday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections
Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET WARMINSTER, Pa., May 11,.
- GlobeNewswire
Arbutus to Report First Quarter 2020 Financial Results
WARMINSTER, Pa., May 04, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled.
- Simply Wall St.
The Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Have Been Trimming Their Sales Forecasts
One thing we could say about the analysts on Arbutus Biopharma Corporation (NASDAQ:ABUS) - they aren't optimistic...
- Benzinga
The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance
Here's a roundup of top developments in the biotech space over the last 24 hours.None of the NYSE- or Nasdaq-listed biotech stocks hit 52 week highs Thursday.Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 26) * Aptevo Therapeutics Inc (NASDAQ: APVO) (reacted to its fourth-quarter results) * TFF Pharmaceuticals Inc (NASDAQ: TFFP)Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.Stocks In Focus Sanofi's Multiple Myeloma Drug Gets Positive European Regulatory Agency Committee Opinion Sanofi SA (NASDAQ: SNY) said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for Sarclisa in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.In premarket trading Friday, the stock was up 1.28% to $43.50.Translate Bio, Sanofi to Partner for COVID-19 Vaccine Research Translate Bio Inc (NASDAQ: TBIO) Bio said it will collaborate with Sanofi to develop a mRNA vaccine for COVID-19, joining a host of companies working on a vaccine for the SARS-CoV-2. Translate Bio has begun to produce multiple mRNA constructs, and it expects to use its mRNA platform for developing SARS-CoV-2 vaccine candidate.Separately, Translate Bio said the FDA has granted Rare Pediatric Disease designation for MRT5005 for the treatment of cystic fibrosis, its first inhaled mRNA therapeutic. The company also said it expects interruptions in enrolment, dosing and follow-up in the ongoing Phase 1/2 trial in patients with cystic fibrosis.It said it will provide an updated timing on the interim data readout of the additional single-ascending dose group and the multiple ascending dose portion of the trial at a later date.Translate Bio shares were jumping 21.95% to $12.50 in premarket trading Friday.TherapeuticsMD Suspends FY20 Guidance, Announces Cost Cuts TherapeuticsMD Inc (NASDAQ: TXMD) pre-announced first-quarter total net revenues of more than $11 million, while analysts expect revenues of $11.64 million. The company said it is suspending its 2020 guidance, citing the unknown impact of COVID-19 on its business.The company also announced measures to cut or defer more than $30 million in annual spending.The stock was slipping 7.75% to $1.19 in premarket trading Friday.Zealand Announces Private Placement of Common Stock Danish biotech ZEALAND PHARMA/S ADR (NASDAQ: ZEAL) announced a private placement and directed share issue of 741,816 new ordinary shares to a U.S.-based investor at 185 Danish Krone per new ordinary share. The company said it expects to receive gross proceeds from the placement of about 137,236,000 Danish Krone.The company said it will use the net proceeds for supporting its peptide platform, accelerating development of late stage assets, and prepare for the launch of its first fully-owned asset.Arbutus Announces Positive Early-stage Results For Hepatitis B Drug Arbutus Biopharma Corp (NASDAQ: ABUS) announced positive preliminary results from a Phase 1a/1b clinical study of its RNAi therapy AB-729 in healthy subjects and two cohorts of chronic hepatitis B subjects on nucleos(t)ide antiviral therapy. The study was meant to determine the most effective dose and dosing interval for use in future Phase 2 combination clinical trials.View more earnings on IBB"These encouraging preliminary results demonstrate that AB-729 is a potent RNAi agent capable of reducing HBsAg plasma levels and support its further development as a treatment for people living with chronic hepatitis B," the company said.The stock was advancing 3.98% to $2.35 in premarket trading Friday.Earnings Neubase Therapeutics Inc's (NASDAQ: NBSE) fourth quarter net loss widened from 25 cents in 2018 to 26 cents in 2019, but was narrower than the consensus loss estimate of 32 cents per share. The company said its current cash balance will provide sufficient capital to fund operations through the end of fiscal year 2020.In premarket trading Friday, Neubase shares were rallying 19.28% to $6.99.NovaBay Pharmaceuticals, Inc.'s (NYSE: NBY) fourth-quarter revenues fell from $3.6 million in 2018 to $1.7 million in 2019. The net loss per share widened from 7 cents to 13 cents. Analysts had estimated a loss of 7 cents per share.The stock was plunging 10.92% to 78 cents in premarket trading Friday.aTyr Pharma Inc (NASDAQ: LIFE) reported total revenues of $0.1 million and a loss of $1.54 per share for the fourth quarter of 2019. In the year-ago quarter, the company reported no revenues and a loss of $2.92 per share. The consensus estimate had called for a loss of $1.59 per share for the recent fourth quarter.As of Dec. 31, the company had cash, cash equivalents and investments of about $31.1 million.In premarket trading, the shares were adding 5.84% to $3.26.Vir Biotechnology Inc (NASDAQ: VIR), which is working on a cure for the new coronavirus, reported a decline in its fourth-quarter revenues from $3.1 million in 2018 to $1 million in 2019. The net loss per share widened from $3.05 to 71 cents, while analysts estimated a loss of 67 cents per share for the quarter.The stock was advancing 5% to $33.60 in premarket trading.On The Radar Earnings TELA Bio Inc (NASDAQ: TELA) (before the market open) Zyla Life Sciences (OTC: ZCOR) (before the market open) Ocugen Inc (NASDAQ: OCGN) (before the market open) Altimmune Inc (NASDAQ: ALT) (before the market open)See more from Benzinga * The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger * The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down * Novavax Shares Rally On Flu Vaccine Study Results: What You Need To Know(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
Arbutus Biopharma Corporation (ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced positive preliminary results from a Phase 1a/1b clinical trial (AB-729-001) in healthy subjects and two cohorts of chronic hepatitis B subjects on nucleos(t)ide antiviral therapy, all of whom received a single subcutaneous injection of AB-729. AB-729-001 is an ongoing Phase 1a/1b clinical trial designed to determine the most effective dose and dosing interval for use in future Phase 2 combination clinical trials.
- Benzinga
The Daily Biotech Pulse: Trevana Pain Drug Resubmission Accepted For Review, Can-Fite To Explore Treatment For COVID-19
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 4) * 89bio Inc (NASDAQ: ETNB) * Arcus Biosciences Inc (NYSE: RCUS) * Arcturus Therapeutics Ltd (NASDAQ: ARCT)(announced a partnership with Duke-NUS Medical School to develop a COVID-19 vaccine for Singapore) * Cue Biopharma Inc (NASDAQ: CUE) * IGM Biosciences Inc (NASDAQ: IGMS) * Inovio Pharmaceuticals Inc (NASDAQ: INO) * Ocular Therapeutix Inc (NASDAQ: OCUL)(reacted to its preliminary fourth-quarter results and interim data from a Phase 1 study evaluating its eye implant OTX-TKI in patients with wet age-related macular degeneration) * Quest Diagnostics Inc (NYSE: DGX) * Regeneron Pharmaceuticals Inc (NASDAQ: REGN)(CEO Leonard Schleifer reportedly told CNBC the company hopes to produce COVID-19 treatment candidate that could be ready for human testing by August) * Revolution Medicines Inc (NASDAQ: RVMD) (IPOed mid-February) * SpringWorks Therapeutics Inc (NASDAQ: SWTX) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX)(reacted to the company's fourth-quarter results) * Syneos Health Inc (NASDAQ: SYNH) * Viela Bio Inc (NASDAQ: VIE)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 4) * Alterity Therapeutics Ltd (NASDAQ: ATHE) * AngioDynamics, Inc. (NASDAQ: ANGO) * Aptevo Therapeutics Inc (NASDAQ: APVO) * CASI Pharmaceuticals Inc (NASDAQ: CASI) * Enlivex Therapeutics Ltd (NASDAQ: ENLV) * Evogene Ltd (NASDAQ: EVGN)(reacted to fourth-quarter results) * Evolus Inc (NASDAQ: EOLS)(reacted to comments by Korean drug maker Medytox about an ITC case brought up by the company against Daewoong and partner Evolus on intellectual property related to Medytox' botulinum toxin) * Mylan NV (NASDAQ: MYL) * Orthofix Medical Inc (NASDAQ: OFIX) * Passage Bio Inc (NASDAQ: PASG)(IPOed last week) * Titan Medical Inc. (NASDAQ: TMDI)See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates Stocks In Focus Co-Diagnostics' COVID-19 Detection Kit Demand Surges Co-Diagnostics Inc (NASDAQ: CODX) said demand, both domestic and international, surged for its COVID-19 detection kits in recent weeks, leading to increased product shipments. The increase comes after the FDA changed its policy Feb. 20 and the number of cases testing positive for the disease burgeoned worldwide.The stock was surging 27.17% to $15.26 in pre-market trading.Castle Biosciences Gets First Patent For Skin Cancer Gene Expression Profile Test Skin cancer diagnostic company Castle Biosciences Inc (NASDAQ: CSTL) said the U.S. patent office has issued it the first U.S. patent related to the DecisionDx -Melanoma gene expression profile test for patients with cutaneous melanoma.FDA Accepts Trevena's Resubmitted NDA for Pain Drug Trevena Inc (NASDAQ: TRVN) said the FDA has acknowledged the receipt of and accepted the resubmitted NDA for intravenous oliceridine, its lead investigational asset, for the management of moderate-to-severe acute pain. The PDUFA date has been set for Aug. 7.In pre-market trading, shares were rising 12.35% to 91 cents.Can-Fite To Explore Treatment For COVID-19 Can-Fite BioPharma Ltd. (NASDAQ: CANF) said it is exploring a collaboration to explore if its investigational asset Piclidenoson, being evaluated for autoimmune inflammatory disease, is effective against coronavirus following reports that rheumatoid arthritis drugs have been introduced for the treatment of the same.The stock was jumping 26.28% to $1.97 in pre-market trading.RA Medical Says NYSE Accepts Plan to Regain Compliance RA Medical Systems Inc (NYSE: RMED) said the NYSE has accepted the company's business plan to regain compliance with the NYSE listing standards. Late last year, the company was notified by the NYSE regarding flouting of listing standards pertaining to average market capitalization being less than $50 million over a recent consecutive 30 days.MacroGenomics' Chief Medical Officer Resigns to Pursue Another Opportunity MacroGenics Inc (NASDAQ: MGNX) announced the resignation of Jon Wigginton as its SVP, Clinical Development & Chief Medical Officer, effective March 27, as he pursues a new opportunity. The role will be assigned on an interim basis to Ezio Bonvini, who is currently serving as SVP, Research and Chief Scientific Officer, the company said.Morphosys To Issue Additional Shares For Subscription By Incyte As Part of Tafasitamab Licensing Deal Morphosys Ag (NASDAQ: MOR) said its Management Board has resolved to increase the share capital of the company by issuing 907,441 new ordinary shares from the authorized capital to facilitate purchase of 3.63 million ADSs by Incyte Corporation (NASDAQ: INCY). The newly issued shares represent about 2.84% of the registered share capital of MorphoSys prior to the consummation of the capital increase.View more earnings on TRVNIncyte's purchase of ADSs amounting to $150 million or $41.32 per ADS is part of the consideration due to MorphoSys for the former acquiring licensing rights to develop and commercialize the latter's investigational compound tafasitamab.In pre-market trading, MorphoSys shares were slipping 3.70% to $28.89.Earnings Specialty pharma company Opiant Pharmaceuticals Inc (NASDAQ: OPNT), which develops treatment for treating addictions and drug overdose, reported fourth-quarter revenues of $7.7 million compared to $4.8 million in the fourth quarter of 2018. The company reversed to a profit of 20 cents per share from a loss of $2.49 per share last year, while analysts had estimated a loss of $2.13 per share, on average.The stock rallied 17.09% to $13.70 in after-hours trading.Offerings BridgeBio Pharma Inc (NASDAQ: BBIO) priced the upsized offering of $475 million aggregate principal amount of 2.50% convertible senior notes due 2027 in a private offering to qualified institutional buyers. The company said the notes will bear interest at a rate of 2.50% per year, payable semi-annually in arrears on March 15 and Sept. 15 of each year. Beginning Sept. 15, 2020.The company estimates to raise net proceeds of about $463.7 million from the offering.On The Radar Earnings * Arbutus Biopharma Corp (NASDAQ: ABUS) (before the market open) * BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) (before the market open) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) * Xtant Medical Holdings Inc (NYSE: XTNT) (before the market open) * Fulcrum Therapeutics Inc (NASDAQ: FULC) (before the market open) * Syros Pharmaceuticals Inc (NASDAQ: SYRS) (before the market open) * Obseva SA (NASDAQ: OBSV) (before the market open) * OptiNose Inc (NASDAQ: OPTN) (before the market open) * Caladrius Biosciences Inc (NASDAQ: CLBS) (after the close) * Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the close) * BioNano Genomics Inc (NASDAQ: BNGO) (after the close) * Corvus Pharmaceuticals Inc (NASDAQ: CRVS) (after the close) * Eloxx Pharmaceuticals Inc (NASDAQ: ELOX) (after the close)See more from Benzinga * GenMark Spikes Higher On COVID-19 Test Kit Shipment * The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More * How The COVID-19 Outbreak Is Benefiting Biotech Investors(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- GlobeNewswire
Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update
Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa., March 05, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV).
- GlobeNewswire
Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results
WARMINSTER, Pa., Feb. 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled.
- GlobeNewswire
Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer
Arbutus Biopharma Corporation (ABUS), announced today its decision to discontinue AB-452, its first generation orally available hepatitis B (HBV) specific RNA-destabilizer, and to continue research and development of a next generation oral HBV RNA-destabilizer. In October 2018, Arbutus announced its decision to delay the initiation of a planned 28-day Phase 1a/1b clinical trial for AB-452 in order to further evaluate the safety of the compound. This decision was based on findings in 90-day preclinical safety studies in two species.
- Simply Wall St.
Does The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Price Tend To Follow The Market?
If you're interested in Arbutus Biopharma Corporation (NASDAQ:ABUS), then you might want to consider its beta (a...
- Zacks
Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) Stock
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
- Zacks
Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down
Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.
- Insider Monkey
Arbutus Biopharma Corp (ABUS): Hedge Funds In Wait-and-See Mode
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter of 2018. Trends reversed 180 degrees in 2019 amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
